遗传性乳腺癌、卵巢癌、前列腺癌和胰腺癌易感基因BRCA1、BRCA2、PALB2、ATM和CHEK2种系突变携带者的临床实践指南（4.2024）。

Q4 Medicine Klinicka Onkologie Pub Date : 2024-01-01 DOI:10.48095/ccko2024292

P Kleiblová, J Novotný, D Cibula, V Curtisová, O Dubová, L Foretová, A Germanová, M Janatová, O Havránek, M Hojsáková, M Hudcová, M Koudová, V Krutílková, M Palacova, S Paulich, K Petrakova, J Presl, A Puchmajerová, J Soukupová, M Šenkeříková, Z Šimková, H Štěpánková, I Šubrt, I Tachecí, P Tesner, O Urban, K Veselá, Š Vilímová, Z Vlčková, M Vočka, V Weinberger, M Zikán, M Zimovjanová, Z Kleibl

{"title":"遗传性乳腺癌、卵巢癌、前列腺癌和胰腺癌易感基因BRCA1、BRCA2、PALB2、ATM和CHEK2种系突变携带者的临床实践指南（4.2024）。","authors":"P Kleiblová, J Novotný, D Cibula, V Curtisová, O Dubová, L Foretová, A Germanová, M Janatová, O Havránek, M Hojsáková, M Hudcová, M Koudová, V Krutílková, M Palacova, S Paulich, K Petrakova, J Presl, A Puchmajerová, J Soukupová, M Šenkeříková, Z Šimková, H Štěpánková, I Šubrt, I Tachecí, P Tesner, O Urban, K Veselá, Š Vilímová, Z Vlčková, M Vočka, V Weinberger, M Zikán, M Zimovjanová, Z Kleibl","doi":"10.48095/ccko2024292","DOIUrl":null,"url":null,"abstract":"The Guidelines for Clinical Practice for carriers of pathogenic variants in clinically relevant cancer predisposition genes define the steps of primary and secondary prevention that should be provided to these individuals at high risk of developing hereditary cancer in the Czech Republic. The drafting of the guidelines was organized by the Oncogenetics Working Group of the Society for Medical Genetics and Genomics of J. E. Purkyně Czech Medical Society (SLG ČLS JEP) in cooperation with the representatives of oncology and oncogynecology. The guidelines are based on the current recommendations of the National Comprehensive Cancer Network (NCCN), European Society of Medical Oncology (ESMO) and take into account the capacity of the Czech healthcare system.","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The guidelines for clinical practice for carriers of germline mutations in hereditary breast, ovarian, prostate, and pancreatic cancer predisposition genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 (4.2024).\",\"authors\":\"P Kleiblová, J Novotný, D Cibula, V Curtisová, O Dubová, L Foretová, A Germanová, M Janatová, O Havránek, M Hojsáková, M Hudcová, M Koudová, V Krutílková, M Palacova, S Paulich, K Petrakova, J Presl, A Puchmajerová, J Soukupová, M Šenkeříková, Z Šimková, H Štěpánková, I Šubrt, I Tachecí, P Tesner, O Urban, K Veselá, Š Vilímová, Z Vlčková, M Vočka, V Weinberger, M Zikán, M Zimovjanová, Z Kleibl\",\"doi\":\"10.48095/ccko2024292\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The Guidelines for Clinical Practice for carriers of pathogenic variants in clinically relevant cancer predisposition genes define the steps of primary and secondary prevention that should be provided to these individuals at high risk of developing hereditary cancer in the Czech Republic. The drafting of the guidelines was organized by the Oncogenetics Working Group of the Society for Medical Genetics and Genomics of J. E. Purkyně Czech Medical Society (SLG ČLS JEP) in cooperation with the representatives of oncology and oncogynecology. The guidelines are based on the current recommendations of the National Comprehensive Cancer Network (NCCN), European Society of Medical Oncology (ESMO) and take into account the capacity of the Czech healthcare system.\",\"PeriodicalId\":35565,\"journal\":{\"name\":\"Klinicka Onkologie\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Klinicka Onkologie\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.48095/ccko2024292\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klinicka Onkologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.48095/ccko2024292","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

临床相关癌症易感基因致病变异携带者临床实践指南》规定了捷克共和国应为这些遗传性癌症高危人群提供的一级和二级预防措施。该指南由捷克医学会 J. E. Purkyně 医学遗传学和基因组学学会肿瘤遗传学工作组（SLG ČLS JEP）与肿瘤学和妇科肿瘤学代表合作起草。该指南以美国国家综合癌症网络（NCCN）和欧洲肿瘤内科学会（ESMO）的现行建议为基础，并考虑了捷克医疗保健系统的能力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

The guidelines for clinical practice for carriers of germline mutations in hereditary breast, ovarian, prostate, and pancreatic cancer predisposition genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 (4.2024).

The Guidelines for Clinical Practice for carriers of pathogenic variants in clinically relevant cancer predisposition genes define the steps of primary and secondary prevention that should be provided to these individuals at high risk of developing hereditary cancer in the Czech Republic. The drafting of the guidelines was organized by the Oncogenetics Working Group of the Society for Medical Genetics and Genomics of J. E. Purkyně Czech Medical Society (SLG ČLS JEP) in cooperation with the representatives of oncology and oncogynecology. The guidelines are based on the current recommendations of the National Comprehensive Cancer Network (NCCN), European Society of Medical Oncology (ESMO) and take into account the capacity of the Czech healthcare system.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Klinicka Onkologie Medicine-Oncology

CiteScore

1.00

自引率

0.00%

发文量